Diabesity Rounds

CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9

In a phase 3b trial of adults with obesity or overweight and no diabetes, both lower CagriSema dose levels were superior to placebo for bodyweight loss at 68 weeks.

Illustration. Not a photograph of the study.

At a glance

  • At week 68, mean bodyweight fell by 20.7% (1.7 mg each), 21.0% (1.0 mg each) and 2.0% (pooled placebo), efficacy estimand.
  • Most adverse events were mild or moderate and gastrointestinal. No deaths were reported.
  • The trial was funded by Novo Nordisk, measured weight rather than clinical outcomes, and the abstract does not report a direct comparison of the two doses.

Key result

Both CagriSema doses were superior to placebo, cutting bodyweight by 20.7% and 21.0% vs 2.0%.

Relative change in bodyweight from baseline, Week 68

CagriSema 1.7 mg each−20.7%
CagriSema 1.0 mg each−21.0%
Pooled placebo−2.0%

309 participants · 68 weeks · p<0.0001 vs placebo, both doses

Numbers as reported in the source.

The study

REDEFINE 9 was a multicentre, randomised, double-blind within dose level, placebo-controlled, parallel-group phase 3b trial, published in The Lancet Diabetes & Endocrinology. It ran at 24 sites in Canada, France, Germany, the UK and the USA. Funding was from Novo Nordisk.

The trial tested once-weekly subcutaneous cagrilintide-semaglutide (CagriSema) at two dose levels, 1.7 mg each and 1.0 mg each. The authors note that CagriSema 2.4 mg each had already shown clinically meaningful weight loss in global phase 3 studies, and that other dose options might suit individual response and tolerability.

Adults had a BMI of at least 30 kg/m2, or at least 27 kg/m2 with one or more obesity-related complication. People with diabetes were excluded. In total, 309 participants were randomly assigned (2:1:2:1) to CagriSema 1.7 mg each, a matching placebo for that dose level, CagriSema 1.0 mg each, or a matching placebo for that dose level. The placebo arms were pooled for the reported analysis. Treatment lasted 68 weeks, with nutrition and physical activity counselling until week 74. The dose was started at 0.25 mg each and escalated over 12 weeks (1.7 mg arm) or 8 weeks (1.0 mg arm).

The coprimary endpoints were relative change in bodyweight and the proportion losing at least 5% of bodyweight, both at week 68.

What they found

Mean age was 48.0 years and mean BMI was 39.1 kg/m2. Of the participants, 239 (77%) were female. In all, 291 (94%) completed the study and 254 (82%) were on treatment at week 68.

For the efficacy estimand, mean bodyweight fell by 20.7% with CagriSema 1.7 mg each, by 21.0% with 1.0 mg each, and by 2.0% with pooled placebo. The estimated treatment differences versus placebo were -18.8 percentage points (95% CI -21.5 to -16.0) for the 1.7 mg dose and -19.0 percentage points (95% CI -21.8 to -16.2) for the 1.0 mg dose. Both had p<0.0001.

A weight loss of at least 5% was reached by 95.1% with the 1.7 mg dose, 96.3% with the 1.0 mg dose and 33.4% with placebo. The estimated treatment differences were 61.7 percentage points (95% CI 49.5 to 74.0) and 63.0 percentage points (95% CI 51.1 to 74.9), both p<0.0001.

Adverse events were reported by 102 of 103 participants (99%) on the 1.7 mg dose, 98 of 103 (95%) on the 1.0 mg dose and 93 of 102 (91%) on placebo. Most were mild or moderate and gastrointestinal. No deaths were reported.

How much weight to give it

The authors concluded that both dose levels were superior to placebo for weight loss. The design supports this: it was randomised, double-blind within dose level and placebo-controlled, and 94% of participants completed the study.

There are limits. The main reported results are for the efficacy estimand. Only 82% were still on treatment at week 68. The abstract does not report results by treatment-policy estimand. The outcomes are bodyweight measures, not heart, kidney or other clinical outcomes. The trial was funded by Novo Nordisk.

Each dose level had its own matching placebo arm, but the results are reported against pooled placebo. The abstract does not report a direct comparison of the 1.7 mg and 1.0 mg doses, so it cannot show that one dose is equivalent to the other. The abstract also does not report serious adverse events, stopping of treatment because of adverse events, or details of individual gastrointestinal events. Participants had no diabetes, and the trial sites were in five countries. The abstract gives no data for Indian patients.

For your clinic

These results suggest that lower CagriSema dose levels can produce large weight loss over 68 weeks in adults with obesity or overweight and no diabetes. The authors say this may allow more flexible treatment. This does not guide the choice of dose for any one patient.

Read the full paper before drawing practical conclusions. Look especially at tolerability, treatment discontinuation, serious adverse events and the treatment-policy results. Check local guidance and the regulatory status of the combination before using it in practice, as the abstract does not state this. Results in people with diabetes should not be inferred from this trial.

Source

Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.

Wharton S, Broholm C, Horn D et al.. The lancet. Diabetes & endocrinology. 14 November 2026

Read the source · DOI 10.1016/S2213-8587(26)00275-5

Teaching a session? Download this report as a slide (PNG, free to use with credit).

For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.

More on obesity medicine

Go deeper